Advanced

High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer

Paulsson, J.; Rydén, Lisa LU ; Strell, C; Frings, O; Tobin, N.P. ; Fornander, T.; Bergh, J.; Landberg, G.; Ståhl, O. and Östman, A. (2017) In The Journal of Pathology: Clinical Research 3(1). p.38-43
Abstract
Cancer-associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signaling affecting cancer cell drug sensitivity and effects on tumour drug uptake. PDGFRβ is an important regulator of fibroblasts. Experimental studies have linked PDGFRβ-positive fibroblasts to metastasis and also to reduced tumour drug uptake. This study has investigated the potential role of PDGFRβ-positive fibroblasts in response to adjuvant tamoxifen treatment of breast cancer. Analyses of two breast cancer collections from randomized studies analyzing adjuvant tamoxifen... (More)
Cancer-associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signaling affecting cancer cell drug sensitivity and effects on tumour drug uptake. PDGFRβ is an important regulator of fibroblasts. Experimental studies have linked PDGFRβ-positive fibroblasts to metastasis and also to reduced tumour drug uptake. This study has investigated the potential role of PDGFRβ-positive fibroblasts in response to adjuvant tamoxifen treatment of breast cancer. Analyses of two breast cancer collections from randomized studies analyzing adjuvant tamoxifen treatment in early breast cancer demonstrated significant benefit of tamoxifen in the group with low stromal PDGFRβ, which was not observed in the group with high stromal PDGFRβ. In general terms these findings provide novel evidence, derived from analyses of randomized clinical studies, of response-predictive capacity of a marker-defined subset of CAFs and, more specifically, identify stromal PDGFRβ as a marker related to tamoxifen benefit in early breast cancer. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
The Journal of Pathology: Clinical Research
volume
3
issue
1
pages
38 - 43
publisher
John Wiley & Sons
external identifiers
  • wos:000410844100004
ISSN
2056-4538
DOI
10.1002/cjp2.56
language
English
LU publication?
yes
id
af39ca00-7aea-45c2-a685-3b1a0913f2a7
date added to LUP
2016-11-29 11:48:57
date last changed
2018-01-16 13:21:37
@article{af39ca00-7aea-45c2-a685-3b1a0913f2a7,
  abstract     = {Cancer-associated fibroblasts (CAFs) regulate tumour growth, metastasis and response to treatment. Recent studies indicate the existence of functionally distinct CAF subsets. Suggested mechanisms whereby CAFs can impact on treatment response include paracrine signaling affecting cancer cell drug sensitivity and effects on tumour drug uptake. PDGFRβ is an important regulator of fibroblasts. Experimental studies have linked PDGFRβ-positive fibroblasts to metastasis and also to reduced tumour drug uptake. This study has investigated the potential role of PDGFRβ-positive fibroblasts in response to adjuvant tamoxifen treatment of breast cancer. Analyses of two breast cancer collections from randomized studies analyzing adjuvant tamoxifen treatment in early breast cancer demonstrated significant benefit of tamoxifen in the group with low stromal PDGFRβ, which was not observed in the group with high stromal PDGFRβ. In general terms these findings provide novel evidence, derived from analyses of randomized clinical studies, of response-predictive capacity of a marker-defined subset of CAFs and, more specifically, identify stromal PDGFRβ as a marker related to tamoxifen benefit in early breast cancer.},
  author       = {Paulsson, J. and Rydén, Lisa and Strell, C and Frings, O and Tobin, N.P.  and Fornander, T. and Bergh, J. and Landberg, G. and Ståhl, O. and Östman, A.},
  issn         = {2056-4538},
  language     = {eng},
  number       = {1},
  pages        = {38--43},
  publisher    = {John Wiley & Sons},
  series       = {The Journal of Pathology: Clinical Research},
  title        = {High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer},
  url          = {http://dx.doi.org/10.1002/cjp2.56},
  volume       = {3},
  year         = {2017},
}